We created thiazole and oxazole analogues of diaminopimelic acid (DAP) by replacing its carboxyl groups and substituting sulphur for the central carbon atom. Toxicity, ADME, molecular docking, and in vitro antimicrobial studies of the synthesized compounds were carried out. These compounds displayed significant antibacterial efficacy, with MICs of 70–80 µg/mL against all tested bacteria. Comparative values of the MIC, MBC, and ZOI of the synthesized compound were noticed when compared with ciprofloxacin. At 200 µg/mL, thio-DAP (1) had a ZOI of 22.67 ± 0.58, while ciprofloxacin had a ZOI of 23.67 ± 0.58. To synthesize thio-DAP (1) and oxa-DAP (2), l-cysteine was used as a precursor for the L-stereocenter (l-cysteine), which is recognized by the dapF enzyme’s active site and selectively binds to the ligand’s L-stereocenter. Docking studies of these compounds were carried out using the programme version 11.5 Schrodinger to reveal the hydrophobic and hydrophilic properties of these complexes. The docking scores of compounds one and two were −9.823 and −10.098 kcal/mol, respectively, as compared with LL-DAP (−9.426 kcal/mol.). This suggests that compounds one and two interact more precisely with dapF than LL-DAP. Chemicals one and two were synthesized via the SBDD (structure-based drug design) approach and these act as inhibitors of the dapF in the lysine pathway of bacterial cell wall synthesis.

Gastrointestinal stromal tumors (GISTs) present unique diagnostic and therapeutic challenges. This review highlights advancements facilitated by molecularly targeted therapies like imatinib for advanced, metastatic, and high-risk GISTs, underscoring their neoadjuvant/adjuvant utility and the importance of multidisciplinary care. Emerging avenues, including immunotherapy, PI3K/mTOR/HSP90 inhibitors, are examined, reflecting the evolving treatment landscape. Furthermore, it explores distinct clinical considerations for GIST subtypes like spindle cell, epithelioid, mixed, and SDH-deficient tumors. Crucially, identifying predictive biomarkers (molecular alterations, non-coding RNAs, SLITRK3 expression, aberrant DNA methylation, radiomics) is emphasized for optimizing individualized regimens and improving outcomes. Overall, the review highlights the remarkable advances in GIST treatment while emphasizing the need for ongoing research into novel, molecularly tailored therapeutic strategies.

This research aims to investigate the in vitro and in vivo nephroprotective activity of Michelia champaca leaves extracts in gentamicin-induced nephrotoxicity rats. The flavonoid and phenols-rich fractions of Michelia champaca leaves extract were subjected to in silico methods based on in vitro investigations, using renal target proteins. The results of the in vitro antioxidant study of extracts were tested for cytoprotective MTT assay and anti-inflammatory efficacy by protein denaturation assay using human embryonic kidney cells (HEK293). The in vivo nephroprotective potential of the extract was evaluated at a lower dose of 250 mg/kg and a higher dose of 500 mg/kg body weight in gentamicin-induced nephrotoxicity in rats with histopathological investigations. The Michelia champaca hydroalcoholic extract (MCHAE) shows remarkable binding affinity with bonding interactions of flavonoids and phenolics-based ligands observed with the target proteins that provided early information. The in vitro cell lines study revealed no cytotoxicity and better anti-inflammatory effect on HEK293 cells with cytoprotective and nephroprotective efficacy of MCHAE. The in vivo nephroprotective activity improved at a dose of 500mg/kg of MCHAE than Michelia champaca ethanolic extract (MCEE). Histopathological investigations revealed the improvement in gentamicin-induced renal toxicity by the MCHAE orally treated group compared to other groups. These results of MCHAE are more effective than MCEE and have a marked in vitro antioxidant, and cytoprotective effect in HEK293 cell lines, with good interaction scores of ligands in molecular docking studies with nephroprotective potential benefits in gentamicin-induced nephrotoxicity in rats.